When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Das Wichtigste auf einen Blick
Synovial sarcomas are aggressive soft tissue sarcomas in dogs that originate in the tissues lining the joint capsules. The exact cause is unknown, but genetic factors and chronic arthritis could play a role. Affected dogs often show symptoms such as lameness, joint swelling, and pain. Diagnosis requires a thorough examination, often with X-ray and imaging such as CT or MRI, as well as a biopsy to confirm the malignant nature of the tumor. Treatment is multidisciplinary and usually includes surgical removal of the tumor, radiation therapy, and, if necessary, chemotherapy. Pain management is crucial to improve dogs’ quality of life.
However, the prognosis for dogs with synovial sarcoma is often guarded to poor, as these tumors can grow aggressively and spread. Early detection and complete removal offer the best chance of longer survival. Prevention is difficult because the causes are not fully understood; however, regular veterinary examinations, a balanced diet, and avoiding joint injuries can be helpful. Research in this area is investigating genetic and molecular foundations and developing new therapies, including immunotherapy and improved surgical techniques. Advances in imaging and new drugs to inhibit tumor growth are also promising areas of research.
Ursachen
Synovial sarcomas are soft tissue sarcomas that originate in the synovial tissue lining the joint capsules. These tumors are known for their invasive growth into surrounding soft tissues and bones, making them particularly destructive.
The exact causes of synovial sarcomas in dogs are largely unknown. However, it is suspected that genetic factors could play a role. Certain breeds such as Dobermans and German Shepherds seem to be affected more frequently, suggesting a possible genetic predisposition.
Another factor being considered is chronic inflammatory conditions or traumas in the joints, which can increase the risk of developing malignant tumors. This constant irritation could promote cell growth and division, leading to malignant changes.
Symptoms
Symptoms of synovial sarcomas in dogs can start subtly and increase in intensity over time. The most common sign is lameness, which may initially be episodic but can gradually develop into constant lameness. This lameness is often associated with pain, especially with movement or pressure on the affected joint.
In addition, swelling around the affected joint may be observed. This swelling can be firm or soft and may increase in size over time. Dogs with synovial sarcoma may also show general signs of malaise, such as reduced appetite, weight loss, and a decreased activity level.
In advanced stages, movement of the affected joint may be severely restricted, and the dog may show signs of muscle atrophy as the muscles around the joint begin to waste away due to reduced use.
Diagnose
Diagnosing synovial sarcoma typically begins with a thorough clinical examination and a detailed medical history taken by the veterinarian. X-rays are often used as the first diagnostic step to detect changes in the bone around the affected joint, although soft tissue sarcomas are not always visible on X-ray images / radiographs.
Advanced imaging techniques such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) may be needed to assess the spread of the tumor and its relationship to surrounding structures in more detail. These procedures can help determine the size and exact location of the tumor.
A definitive diagnosis usually requires fine-needle aspiration or a biopsy of the tumor for histopathological examination. This examination confirms the malignant nature of the tumor and determines the specific type of sarcoma.
Therapie
Treating synovial sarcomas usually requires a multidisciplinary approach. Surgical removal of the tumor is often the preferred treatment option, especially if it is detected at an early stage. For tumors that have invaded the bone, amputation of the affected limb may be necessary to ensure complete removal.
In addition to surgical removal, radiation therapy can be used to kill remaining cancer cells and reduce the risk of relapse. In some cases, chemotherapy is also considered, especially if the tumor cannot be completely removed or if metastasis is suspected.
Pain management is an essential part of therapy to improve the affected dog’s quality of life. Painkillers and anti-inflammatory medications can help relieve pain and improve mobility.
Prognose und Nachsorge
The prognosis for dogs with synovial sarcoma depends on several factors, including the size and location of the tumor, the presence of metastases, and the response to treatment. In general, the prognosis is guarded to poor, as synovial sarcomas tend to grow aggressively and metastasize to other parts of the body.
Dogs in which the tumor is detected early and completely removed have the best prognosis. Average survival time after diagnosis can range from several months to a year or longer, depending on the effectiveness of treatment and the dog’s overall health.
Prävention
Since the exact causes of synovial sarcomas are not fully understood, there are no specific prevention measures that can reliably prevent the development of these tumors. Nevertheless, some general strategies can help reduce the risk.
Regular veterinary check-ups are crucial to detect early signs of health problems. Dog owners should pay attention to changes in their animals’ gait or mobility and consult a veterinarian quickly if they notice any abnormalities.
A balanced diet and regular exercise can help strengthen a dog’s overall health and immune system, which could potentially reduce the risk of developing malignant tumors. In addition, injuries and chronic joint inflammation should be avoided or treated quickly to prevent long-term damage.
Ausblick auf aktuelle Forschung
Research into synovial sarcomas in dogs is a constantly evolving field focusing on understanding biological mechanisms and developing new treatment strategies. Synovial sarcomas are a rare form of cancer originating from the soft tissues in and around the joints. This type of cancer can be aggressive and requires early detection and treatment to improve the well-being of the affected animal.
Current research projects are investigating the genetic and molecular basis of synovial sarcomas in dogs. Scientists use advanced techniques such as genomic analysis to identify specific genetic mutations associated with the development and progression of these tumors. These findings could help develop targeted therapies that specifically address the molecular characteristics of the tumor.
Another area of research is the development of immunotherapeutic approaches. These methods aim to strengthen the dog’s immune system to fight cancer cells more effectively. Studies on immunotherapy in dogs are promising and could play an important role in treating synovial sarcomas in the future.
In addition to immunotherapy, research is also focusing on improving surgical techniques. Since surgical removal of the tumor is often the primary treatment option, researchers are working to develop minimally invasive techniques that shorten recovery time and improve dogs’ quality of life. Advances in imaging technology enable more precise surgeries and better assessment of tumor size and spread.
Another exciting area is research into drugs that specifically target synovial sarcomas. Clinical trials with new drugs aimed at inhibiting tumor growth and preventing metastases are underway. These studies could open up new treatment options and improve survival rates in dogs with synovial sarcomas.
In summary, research into synovial sarcomas in dogs is a dynamic and promising field. Through ongoing research and innovation, scientists hope to significantly improve the diagnosis, treatment, and management of this disease.
Frequently Asked Questions (FAQs)
1. What is synovial sarcoma in dogs?
2. What symptoms occur in a dog with synovial sarcoma?
3. How is synovial sarcoma diagnosed in dogs?
4. What treatment options are available for dogs with synovial sarcoma?
5. What is the prognosis for a dog with synovial sarcoma?
6. Can synovial sarcomas be prevented in dogs?
7. Which breeds are more susceptible to synovial sarcomas?
8. Are synovial sarcomas painful in dogs?
9. Are there alternative therapies for synovial sarcomas in dogs?
10. How can I help my dog with synovial sarcoma?
Literatur
- Craig, L. E. (2025). Sarcomas of synovial origin in dogs: An updated review. Veterinary Pathology, 62(1), 13–19. https://doi.org/10.1177/03009858241265005
- Craig, L. E., Julian, M. E., & Ferracone, J. D. (2002). The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Veterinary Pathology, 39(1), 66–73. https://doi.org/10.1354/vp.39-1-66
- Fox, D. B., Cook, J. L., Kreeger, J. M., Beissenherz, M., & Henry, C. J. (2002). Canine synovial sarcoma: A retrospective assessment of described prognostic criteria in 16 cases (1994–1999). Journal of the American Animal Hospital Association, 38(4), 347–355. https://doi.org/10.5326/0380347
- Vail, D. M., Powers, B. E., Getzy, D. M., Morrison, W. B., McEntee, M. C., O’Keefe, D. A., Norris, A. M., & Withrow, S. J. (1994). Evaluation of prognostic factors for dogs with synovial sarcoma: 36 cases (1986–1991). Journal of the American Veterinary Medical Association, 205(9), 1300–1307. https://doi.org/10.2460/javma.1994.205.09.1300
- Monti, P., Barnes, D., Adrian, A. M., Beatty, J. A., & Black, A. P. (2018). Synovial cell sarcoma in a dog: A misnomer—Cytologic and histologic findings and review of the literature. Veterinary Clinical Pathology, 47(1), 181–185. https://doi.org/10.1111/vcp.12590
- Wager, A. C., Springer, C., Bergee, R., & Craig, L. E. (2025). Cytokeratin expression by sarcomas does not indicate synovial origin in dogs. Veterinary Pathology, 62(1), 37–44. https://doi.org/10.1177/03009858241279135
- McGlennon, N. J., Houlton, J. E. F., & Gorman, N. T. (1988). Synovial sarcoma in the dog—A review. Journal of Small Animal Practice, 29(3), 139–152. https://doi.org/10.1111/j.1748-5827.1988.tb02272.x